The importance of early diagnosis in chronic obstructive pulmonary disease

Hot Topics in Respiratory Medicine

Volumn 4, Issue 11, 2009, Pages 15-21

  Ferguson, Gary T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; TIOTROPIUM BROMIDE;

AIRWAY OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EARLY DIAGNOSIS; FORCED EXPIRATORY VOLUME; HUMAN; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; SPIROMETRY; SPUTUM;

EID: 77953434323     PISSN: 19739664     EISSN: 20360886     Source Type: Book Series    
DOI: None     Document Type: Review

References (88)

1. Browne G, Roberts J, Gafni A, Weir R, Watt S, Byrne C. More effective and less expensive: lessons from five studies examining community approaches to care. Health Policy 1995;34:95-112.
2. Murphy D, Chapel T, Clark C. Moving diabetes care from science to practice: the evolution of the National Diabetes Prevention and Control Program. Ann Intern Med 2004;140:978-984. (Pubitemid 38685290)
3. Maue SK, Jackson JH IV, Weiss BA, Rivo ML, Jhaveri V, Lennert B. The hypertension management program: identifying opportunities for improvement. J Clin Hypertens 2003;5(Suppl 2):33-40.
4. Stamler J, Stamler R. Intervention for the prevention and control of hypertension and atherosclerotic diseases: United States and international experience. Am J Med 1984;76:13-36. (Pubitemid 14151606)
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.
6. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. In Surveillance Summaries, MMWR Morb Mortal Wkly Rep 2002;51(6):1-16.
7. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-1259.
8. Buist AS, McBurnie MA, Vollmer WM, et al; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-750.
9. Geijer RM, Sachs AP, Verheij TJ, Salomé PL, Lammers JW, Hoes AW. Incidence and determinants of moderate COPD (GOLD II) in male smokers aged 40-65 years: 5-year follow up. Brit J Gen Practice 2006;56:656-661.
10. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805.
11. de Marco R, Accordini S, Cerveri I, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004;59:120-125. (Pubitemid 38223482)
12. Coultas DB, Mapel D, Gagnon R, Lydick E. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med 2001;164:372-377. (Pubitemid 32778201)
13. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993;328:1017-1022. (Pubitemid 23095687)
14. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Accessed November 30, 2008. Available at: www.goldcopd.org.
15. Celli B, MacNee W. ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a Summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946. (Pubitemid 38807371)
16. Bellamy, D, Bouchard J, Henrichsen S, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006;15:48-57. (Pubitemid 43155766)
17. Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007;147:633-638. (Pubitemid 351664484)
18. Zoia MC, Corsico AG, Beccaria M, et al. Exacerbations as a starting point of pro-active chronic obstructive pulmonary disease management. Respir Med 2005;99:1568-1575. (Pubitemid 41683937)
19. Han MK, Kim MG, Mardon R, et al. Spirometry utilization for COPD: how do we measure up? Chest 2007;132:403-409. (Pubitemid 47282369)
20. Burrows B. Epidemiologic evidence for different types of chronic airflow obstruction. Am Rev Respir Dis 1991;143:1452-1455.
21. Sciurba FC. Physiologic similarities and differences between COPD and asthma. Chest 2004;126:117S-124S.
22. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003;22:268-273. (Pubitemid 36986996)
23. Lee TA, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest 2006;129:1509-1515. (Pubitemid 43894979)
24. The Smoking Cessation Clinical Practice Guideline Panel and Staff: The agency for health care policy and research smoking cessation clinical practice guidelines. JAMA 1996;275:1270-1280.
25. Anthonisen NR, Connett JE, Murray RP; Lung Health Study Research Group. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-679.
26. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality. Ann Intern Med 2005;142:233-239.
27. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease - bronchodilators. Proc Am Thorac Soc 2007;4:526-534. (Pubitemid 47547847)
28. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994;105:1411-1419.
29. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-965.
30. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the diskus inhaler for the treatment of COPD. Chest 2003;124:834-843. (Pubitemid 37123298)
31. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224. (Pubitemid 34162820)
32. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789. (Pubitemid 46294610)
33. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-1554.
34. Celli B, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: Results from the TORCH Study. Am J Respir Crit Care Med 2008;178:332-338.
35. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;10:1099-1108.
36. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006;27:547-555. (Pubitemid 43372529)
37. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-326. (Pubitemid 41266605)
38. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653. (Pubitemid 38787999)
39. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-721. (Pubitemid 39140629)
40. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax 2007;62:938-943. (Pubitemid 350084490)
41. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-743.
42. Benfield T, Lange P, Vestbo J. COPD stage and risk of hospitalization for infectious disease. Chest 2008;134:46-53. (Pubitemid 352008762)
43. Donaldson GC, Wedzicha JA. COPD exacerbations.1: epidemiology. Thorax 2006;61:164-168.
44. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006;100:115-122.
45. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Löfdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005;6:98-107. (Pubitemid 41410141)
46. Bridevaux PO, Gerbase MW, Probst-Hensch NM, C Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1. Thorax 2008;63:768-774.
47. The Lung Health Study Research group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-1909.
48. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-1953. (Pubitemid 29288270)
49. Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:622-629.
50. Beeh KM, Beier J, Buhl R, Stark-Lorenzen P, Gerken F, Metzdorf N. Efficacy of tiotropium bromide (spiriva) in patients with chronic obstructive pulmonary disease (COPD) of different severities. Pneumologie 2006;60:341-346. (Pubitemid 44046752)
51. Johansson G, Lindberg A, Romberg K, Nordström L, Gerken F, Roquetd A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J 2008;17:169-175.
52. Adams SG, Anzueto A, Briggs DD Jr, Menjoge SS, Kesten S. Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respir Med 2006;100:1495-1503. (Pubitemid 44172062)
53. Clark CJ, Cochrane LM, Mackay E, et al. Skeletal muscle strength and endurance in patients with mild COPD and the effects of weight training. Eur Respir J 2000;15:92-97. (Pubitemid 30068942)
54. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation. Chest 2007;131;1S-42S.
55. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults. A consensus statement from the National Lung Health Education Program. Chest 2000;117:1146-1161. (Pubitemid 30228377)
56. AHRQ Minnesota Evidence-based Practice Center of the Agency for Healthcare Research and Quality. Use of spirometry for case finding, diagnosis, and management of COPD. Publication No. 05-E017-2, August 2005.
57. Chuong JJH. A screening primer: basic principles, criteria, and pitfalls of screening with comments on colorectal carcinoma. J Clin Gastroenterol 1983;5:229-233.
58. Stoller JK. Pulmonary function testing as a screening technique. Respir Care 1989;34:611-625. (Pubitemid 19170477)
59. Marshall KG. Prevention. How much harm? How much benefit? Can Med J 1996;154:1493-1499 and 155:169-176 (series).
60. Walters JA, Hansen EC, Johns DP, Blizzard EL, Walters EH, Wood-Baker R. A mixed methods study to compare models of spirometry delivery in primary care for patients at risk of COPD. Thorax 2008;63:408-414. (Pubitemid 351692347)
61. Enright P. The use and abuse of office spirometry. Prim Care Respir J 2008;17:238-242.
62. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity, and under-diagnosis of COPD in primary care settings. Thorax 2008;63:402-407. (Pubitemid 351692346)
63. Enright P. Provide GPs with spirometry, not spirometers. Thorax 2008;63:387-388. (Pubitemid 351692340)
64. Walker PP, Mitchell P, Diamantea F, Warburton CJ, Davies L. Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J 2006;28:945-952. (Pubitemid 46331963)
65. van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing COPD in general practice: cross-sectional case finding study. BMJ 2002;324:1370.
66. Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003;123:1916-1923. (Pubitemid 36706712)
67. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006;61:869-873. (Pubitemid 44570307)
68. Morris JF, Temple W. Spirometric "lung age" estimation for motivating smoking cessation. Prev Med 1985;14:655-662.
69. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008;336;598-600.
70. Kotz D, Wesseling G, Huibers MJ, van Schayck OC. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 2009 Jan 7. [Epub ahead of print]
71. Calverley PM, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D. Development of a population-based screening questionnaire for COPD. COPD 2005;2:225-232.
72. Tinkelman DG, Price DB, Nordyke RJ, et al. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 2006;73:296-305. (Pubitemid 43725786)
73. Martinez FJ, Raczek AE, Seifer FD, et al. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD 2008:5:85-95.
74. Tinkelman DG, Price D, Nordyke RJ, Halbert RJ. COPD screening efforts in primary care: what is the yield? Prim Care Respir J 2007;16:41-48. (Pubitemid 46364355)
75. Kotz D, Nelemans P, van Schayck CP, Wesseling GJ. External validation of a COPD diagnostic questionnaire. Eur Respir J 2008;31:298-1230
76. Geijer RM, Sachs AP, Verheij TJ, Lammers JW, Salomé PL, Hoes AW. Are patient characteristics helpful in recognizing mild COPD (GOLD I) in daily practice? Scand J Primary Health Care 2006;24:237-242.
77. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:13.
78. Mannino DM, Etzel RA, Flanders WD. Do the medical history and physical examination predict low lung function? Arch Intern Med 1993;153:1892-1897.
79. Price DB, Tinkelman DG, Halbert RJ, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006;73:285-295. (Pubitemid 43739190)
80. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice. Chest 2004;125;1394-1399.
81. van den Boom G, van Schayck CP, Rutten-van Molken MP, et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population: results and economic consequences of the DIMCA program. Am J Respir Crit Care Med 1998;158:1730-1738.
82. Albers M, Schermer T, Heijdra Y, Molema J, Akkermans R, van Weel C. Predictive value of lung function below normal range and respiratory symptoms for progression of COPD. Thorax 2008;63:201-207.
83. Rodarte JR, Hyatt RE, Rehder K, Marsh HM. New tests for the detection of obstructive pulmonary disease. Chest 1977;72:762-768. (Pubitemid 8253645)
84. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:6-14. (Pubitemid 43955238)
85. Thurlbeck WM, Müller NL. Emphysema: definition, imaging, and quantification. Am J Roentgenol 1994;163:1017-1025.
86. Friedmann PJ. Imaging studies in emphysema. Proc Am Thorac Soc 2008;5;494-500.
87. Ramsey SD, Hobbs FD. Chronic obstructive pulmonary disease, risk factors, and outcome trials. comparisons with cardiovascular disease. Proc Am Thorac Soc 2006;3:635-640. (Pubitemid 44411633)
88. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J 2008;15(Suppl A):1A-8A. (Pubitemid 351566057)